Items Tagged ‘targeted therapy’

January 12, 2018

Combining T-VEC Herpes Virus With Keytruda Immunotherapy Shows Promise for Treating Advanced Melanoma

By

CancerConnect News: UCLA scientists have developed a potential new treatment for melanoma that has shown promising early clinical results.  In a two-year UCLA-led study, nearly two-thirds of people with advanced melanoma responded positively to a treatment that combines the immunotherapy drug keytruda (pembrolizumab) with a herpes virus called T-VEC (talimogene laherpareovec). Researchers found that the […]

View full entry

Tags: immunotherapy, keytruda, Melanoma, News, Precision Cancer Medicine, T-VEC, targeted therapy


January 8, 2018

Cancer Patients are Relatively Unaware of the Role of Precision Cancer Medicine, Genomics and Biomarker Testing

By

CancerConnect News: Precision cancer medicines and the companion tests used to identify them are increasingly important in the management of cancer.  It is important to understand how aware patients are of these evolving treatment options and whether they are being discussed with their doctors. Our recent survey suggests that only one third of cancer patients […]

View full entry

Tags: Biomarkers, cancer connect, General, genomics, News, Precision Cancer Medicine, targeted therapy


January 8, 2018

Ulixertinib A First-in-class ERK Inhibitor Shows Early Efficacy in Patients With Advanced Cancers

By

CancerConnect News: The novel ERK1/2 kinase inhibitor ulixertinib displayed an acceptable safety profile and had clinical activity in patients whose cancers had mutations in the MAPK cell-signaling pathway, according to data from a recent phase 1 clinical trial.  Based on data from this trial, ulixertinib has received the U.S. Food and Drug Administration’s Fast Track […]

View full entry

Tags: Colon Cancer, ERK inhibitor, Lung Cancer, MAPK/ERK, Melanoma, News, Precision Cancer Medicine, targeted therapy, ulixertinib


December 13, 2017

Mogamulizumab Superior to Vorinostat in Cutaneous T Cell Lymphoma

By

Results were recently presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta from a international comparative clinical trail evaluating mogamulizumab in patients with previously treated cutaneous T-cell lymphoma (CTCL). Precision cancer medicine utilizes molecular diagnostic testing, including DNA sequencing, to identify cancer-driving abnormalities in a cancer’s genome. Once a […]

View full entry

Tags: American Society of Hematology, ASH, Cutaneous T Cell Lymphoma, Mogamulizumab Vorinostat, News, non-hodgkin lymphoma, Non-Hodgkin's Lymphoma, Precision Cancer Medicine, T-Cell Non-Hodgkin's Lymphoma, targeted therapy


September 21, 2017

Alecensa Appears Superior to Xalkori in ALK positive NSCLC Involving the Brain

By

The results from two separate clinical studies comparing Alecensa® (alectinib) to Xalkori (crizotinib) presented at the European Society for Medical Oncology in Madrid demonstrate that Alecensa®  s superior in treating non small cell lung caner (NSCLC) that has spread to the brain in anaplastic lymphoma kinase (ALK) gene positive NSCLC. Non-squamous NSCLC is the most […]

View full entry

Tags: Alecensa, alectinib, alk, anaplastic lymphoma kinase, brain metastases, crizotinib, gene positive NSCLC, Lung Cancer - Non-Small Cell, News, non small cell lung caner, nsclc, Precision Cancer Medicine


September 5, 2017

FDA Approves Mylotarg for Treatment of Acute Myeloid Leukemia

By

The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, AML, CD33 antigen, gemtuzumab ozogamicin, Leukemia, Mylotarg, News, Precision Cancer Medicine, targeted therapy